Myltega 50 mg FC tablet
PDF Leaflet Revision Date: 05/04/2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults.
Dosage (summary)
50 mg once daily for treatment-nau00efve; 50 mg twice daily for integrase inhibitor resistant.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Risk of neural tube defects in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels
- Metformin contraindicated
- Antacids decrease absorption
Contraindications
- Hypersensitivity to dolutegravir
- Moderate/severe hepatic impairment
- Dofetilide
- Pilsicainide
Common side effects
- Insomnia
- Nausea
- Rash
- Fatigue
- Headache
Counselling Points
- Take without food
- Monitor for hypersensitivity
- Use effective contraception in women of childbearing potential
Serious warnings
- Hypersensitivity reactions
- Immune Reconstitution Syndrome
- Osteonecrosis risk
Important Disclaimer
The Myltega 50 mg FC tablet professional information leaflet below is the property of Mylan and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
